Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
ScienceAlert on MSN12h
FDA-Approved Nasal Spray For Depression Is First Of Its Kind
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
IFLScience21h
FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
Interesting Engineering on MSN21h
US approves first nasal spray for major depressive disorder, PTSD conditions
Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...
BioSpace17h
J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
NFL14h
C.J. Gardner-Johnson
The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience.
Indiatimes15h
Prism Johnson Share Price
Prism Johnson Ltd., incorporated in the year 1992, is a Mid Cap company (having a market cap of Rs 7,203.54 Crore) operating in Cement sector. Prism Johnson Ltd. key Products/Revenue Segments include ...